John Moroney, MD, and Katherine Kurnit, MD, MPH, emphasize the importance of timing in gynecologic cancer clinical trials.

This case, to our knowledge, is the first reported in gynecologic oncology to demonstrate the feasibility of safely delivering HIPEC with cisplatin in a patient with prior carboplatin hypersensitivity. As HIPEC adoption expands in platinum-sensitive recurrent ovarian cancer, platinum hypersensitivit …

Novel laparoscopic technique allowing safe removal of large cystic abdominopelvic mass. Posterior fornix entry provides controlled access in complex or limited-access cases. Dual drawstring containment bag ensures sealed, spill-free drainage and ...

Our results suggest an observed association between platinum-based chemotherapy and improved outcomes in patients with ovarian carcinosarcoma following optimal cytoreductive surgery. Given that this is a small retrospective analysis, there is a severe selection bias and no formal non-inferiority des …

In women with Stage I-III EEC treated at a single tertiary referral center, we did not find differences in outcomes when analyzed by ADI or race. Given previously reported racial disparities in outcom...

An NNMT inhibitor reduces tumour burden and metastasis in multiple mouse cancer models and restores immune checkpoint blockade efficacy by decreasing cancer-associated-fibroblast-mediated recruitment ...

Schweizer et al. profile the tumor progression from non-invasive serous borderline tumors of the ovary to metastatic low-grade serous ovarian cancer. By integrating cell-type resolved Deep Visual Proteomics and spatial transcriptomics, they identify and validate several drivers of transformation as well as a novel combination treatment for this chemo-resistant disease.